Completed PHASE4 INTERVENTIONAL 2-arm NCT00531167

Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B

Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B

Sponsor: GlaxoSmithKline

Conditions Chronic Hepatitis B

Interventions combination of lamivudine+adefovir vs entecavir

Updated 6 times since 2017 Last updated: Oct 18, 2012 Started: Apr 30, 2007 Primary completion: Apr 30, 2011 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00531167, this PHASE4 trial focuses on Chronic Hepatitis B and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Korea University

Data source: Korea University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ansan, South Korea
• Seoul, South Korea